Cyclazodone is a centrally acting stimulant drug developed by the American Cyanamid Company in the 1960s. It is structurally related to pemoline and thozalinone, displaying a favorable therapeutic index and safety margin compared to pemoline and other N-lower-alkyl-substituted pemoline derivatives.
Cyclazodone has been noted for its potential to reduce fatigue and act as an anorectic. It is classified as an excitant with unique properties, showing less stimulatory activity and toxicity compared to amphetamine.
Safety information is limited as it has not been evaluated by the FDA for human use, though studies on mice suggest it exhibits less cardiotoxic and hepatotoxic effects than D-amphetamine.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Cyclopropyl Pemoline-d5, 2-cyclopropylimino-5-(2, 3, 4, 5, 6-pentadeuteriophenyl)-1, 3-oxazolidin-4-one, CyclopropylPemoline-d5 |
|---|---|
| IUPAC Name | 2-cyclopropylimino-5-(2, 3, 4, 5, 6-pentadeuteriophenyl)-1, 3-oxazolidin-4-one |
| CAS | 1246817-86-6 |
| Molecular Weight | 221.27 |
| Molecular Formula | C12H12N2O2 |
| SMILES | [2H]C1=C(C(=C(C(=C1[2H])[2H])C2C(=O)NC(=NC3CC3)O2)[2H])[2H] |